Michael Vi/iStock Editorial via Getty Images
AbbVie (NYSE:ABBV) announced Monday a setback for a Phase 3 trial designed to test its Roche (OTCQX:RHHBF)-partnered leukemia therapy venetoclax as part of a combination regimen against blood cancer myelodysplastic syndrome (MDS).
Citing data from its global Phase 3 VERONA trial, the Illinois-based drugmaker said a combination regimen involving venetoclax for newly diagnosed patients with higher-risk MDS failed to reach the primary endpoint of overall survival.
The randomized trial was designed to test venetoclax administered with azacitidine, a cancer medicine marketed as Vidaza by Bristol Myers Squibb (BMY), versus azacitidine plus placebo.
There were no new safety signals, AbbVie (NYSE:ABBV) said, adding that VERONA data will be presented at a future medical event and/or posted in a healthcare publication.
Venetoclax, branded as Venclexta/Venclyxto, is available in the U.S. for blood disorders, including chronic lymphocytic leukemia and acute myeloid leukemia, as a single agent or in combination with other drugs.
More on AbbVie, Roche Holding
- AbbVie: Margin Clarity, Dividend Durability Awaited
- AbbVie Moves From Blockbuster Loss To Market Domination
- AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth
- Prothena jumps as partner Roche to advance Parkinson’s drug into late-stage studies
- Sarepta crashes after second death linked to Roche-partnered Elevidys